We still wait on the Middle East to see if we need to add another layer of macro worry to the markets. The longer we go on the more likely tension settle but it still seems to rest on the scale of the Israeli response and whether it compels Iran to respond. A tit-for-tat spiral […]
April 15th Biotech Update
Did we dodge the Middle East risk? We did to a certain extent, but I do not think we are completely out of the woods yet. If Israel decided not to response, then I would be quite confident that the risks are significantly lower but it seems like Israel is going to respond and they […]
April 12th Biotech Update
I sort of figured that even the news of some M&A was not going to drastically change the character of the market. I am progressively become more pessimistic about the market and sector. It has little to do with the fundamentals of the sector and a lot to do with the macro structure in which […]
April 11th Biotech Update
Unfortunately, not much has changed since I noted that the sector is back in the interest rate slump. We were negative for the year and that was completely predicable once the interest rate specter raised its head once again. There is no chance that we get a sustained rally as long as we are in […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
